What are the indications, dosing schedule, contraindications, and monitoring recommendations for bupropion?

Bupropion: Clinical Overview

Bupropion is FDA-approved for major depressive disorder and seasonal affective disorder, and is also highly effective for smoking cessation, with standard dosing of 150 mg once daily for 3 days, then 150 mg twice daily (maximum 300 mg/day), initiated 1-2 weeks before the target quit date. 1, 2

Primary Indications

FDA-Approved Uses

• Major Depressive Disorder (MDD): Effective as monotherapy with efficacy comparable to SSRIs 2, 3
• Seasonal Affective Disorder (SAD): Initiated in autumn prior to symptom onset 2
• Smoking Cessation: First non-nicotine pharmacotherapy approved for tobacco dependence 1, 4

Off-Label Uses

• Weight Management: As naltrexone-bupropion combination for obesity (BMI ≥30 or ≥27 with weight-related complications) 5
• ADHD: Mixed evidence with limited quality data 6

Dosing Schedules

For Smoking Cessation

Start 1-2 weeks before quit date 1:

• Days 1-3: 150 mg orally once daily
• Day 4 through 7-12 weeks: 150 mg orally twice daily if tolerated
• Maximum: 300 mg per day
• Duration: 7-12 weeks initially; may extend to 6-12 months for continued cessation 1

For Major Depressive Disorder

• Starting dose: 150 mg once daily 2
• Target dose: 300 mg once daily after 4 days 2
• Maximum: 450 mg per day (not to exceed in any circumstance) 2

For Naltrexone-Bupropion Combination (Obesity)

Weekly titration schedule 5:

• Week 1: 1 tablet (8 mg naltrexone/90 mg bupropion) once daily in morning
• Week 2: 1 tablet twice daily
• Week 3: 2 tablets in morning, 1 in afternoon
• Week 4+: 2 tablets twice daily (maintenance dose)
• Avoid second dose late in day to minimize insomnia
• Discontinue if <5% weight loss after 12 weeks at maintenance dose 5

Absolute Contraindications

Do not prescribe bupropion in patients with 1, 2:

1. Seizure disorder or conditions increasing seizure risk:

   • Current seizure disorder
   • Brain metastases
   • History of stroke
   • Bulimia or anorexia nervosa (current or prior diagnosis)
   • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs

2. MAO inhibitor use:

   • Within 14 days of MAOI use (increased hypertensive reaction risk) 1, 2
   • Do not start MAOIs within 14 days of stopping bupropion
   • Includes linezolid or IV methylene blue 2

3. Other absolute contraindications:

   • Known hypersensitivity to bupropion 2
   • Closed-angle glaucoma 1
   • Concurrent tamoxifen use 1

4. For naltrexone-bupropion combination:

   • Patients requiring short-term or long-term opioid therapy 5
   • Uncontrolled hypertension 5
   • End-stage renal disease 5

Dose Adjustments for Special Populations

Hepatic Impairment

• Moderate to severe: 150 mg every other day 2
• Mild: Consider reducing dose and/or frequency 2
• For naltrexone-bupropion: Maximum 1 tablet daily in moderate-severe impairment 5

Renal Impairment

• Consider reducing dose and/or frequency 2
• For naltrexone-bupropion: Reduce to 1 tablet twice daily in moderate-severe impairment; avoid in ESRD 5

Monitoring Recommendations

Essential Monitoring Parameters

Blood Pressure 7, 5:

• Monitor before initiating treatment
• Monitor periodically during treatment
• Bupropion can increase blood pressure; avoid in uncontrolled hypertension

Neuropsychiatric Symptoms 1, 2:

• Monitor for development or worsening of:
  • Depression and suicidal ideation/behavior (especially in patients <25 years)
  • Hostility, agitation, anxiety, panic
  • Psychosis, hallucinations, paranoia, delusions
  • Mania/hypomania (screen for bipolar disorder before initiating)
• Action: Discontinue immediately if serious neuropsychiatric symptoms occur 1

Important caveat: A large multicenter RCT (EAGLES trial, n=8,058) found that neuropsychiatric adverse events with bupropion were NOT significantly increased relative to nicotine patches or placebo in patients with or without psychiatric disorders 1. However, the FDA black box warning remains, and clinical vigilance is warranted.

For Naltrexone-Bupropion Combination 5:

• Serum bicarbonate (for topiramate component if used)
• Hydration status if taking insulin or sulfonylureas
• Signs/symptoms of pancreatitis or gallbladder disorders

Seizure Monitoring:

• Risk is approximately 1 in 1,000 at recommended doses 4
• Discontinue permanently if seizure occurs 2

Common Adverse Effects

Most frequent (≥5% and ≥2× placebo) 2:

• Dry mouth (most common)
• Insomnia (dose late in day increases risk)
• Nausea
• Headache
• Dizziness
• Agitation/anxiety
• Tremor
• Sweating

Weight effects: More likely to cause weight loss than gain (mean 0.5-1.0 kg loss) 8, making it advantageous for patients concerned about weight gain

Sexual dysfunction: Very low rates compared to SSRIs 3, 9

During buildup phase for naltrexone-bupropion 10:

• Nausea/vomiting: 23.5%
• Headaches: 19.4%
• Constipation: 28.6%

Clinical Pearls and Pitfalls

Advantages Over Other Antidepressants

• Less sexual dysfunction than SSRIs 3, 9
• Weight loss rather than gain 8, 9
• Less somnolence than tricyclics 3
• Dual benefit for smoking cessation in depressed smokers 5

Common Pitfalls to Avoid

1. Seizure risk management:

   • Never exceed 300 mg per day for smoking cessation 1
   • Never exceed 450 mg per day for any indication 2
   • Gradual dose titration is mandatory 2
   • Screen carefully for seizure risk factors before prescribing

2. Drug interactions:

   • CYP2B6 inducers (ritonavir, efavirenz, carbamazepine, phenobarbital, phenytoin) may require dose increase but not exceeding maximum 2
   • Avoid with MAOIs (14-day washout required) 2
   • For naltrexone-bupropion: Hold before procedures requiring opioids 5

3. Smoking cessation specific:

   • Initiate 1-2 weeks BEFORE quit date (not on quit date) 1
   • Combine with behavioral support for optimal outcomes 1, 4
   • Can be combined with NRT safely 1
   • Therapy may be extended to 6-12 months to prevent relapse 1

4. Discontinuation rates:

   • In real-world obesity treatment, 52.7% discontinued within 12 months 10
   • Side effects during titration are common but often transient 11
   • Slow titration and symptom management improve adherence

Special Populations

Oncology patients 1:

• Contraindicated in brain metastases (seizure risk)
• Nausea may be problematic during chemotherapy
• Weigh substantial benefits of smoking cessation against neuropsychiatric risks

Cardiovascular disease:

• No significant increase in major cardiovascular adverse events 12
• Monitor blood pressure regularly 7, 5

Bipolar disorder:

• Screen all patients before initiating 2
• Phase-shifting risk similar to other antidepressants (not lower as previously thought) 13